Walvax publishes safety and non-inferior immunogenicity results of its MPV ACYW135 compared with Menactra® in Human Vaccines & Immunotherapeutics
ㅤㅤㅤ
ㅤㅤㅤ
Walvax publishes data on safety, immunogenicity and immune persistence from the Phase 2 trial of its HPV2 vaccine Walrinvax™ in Human Vaccines & Immunotherapeutics
ㅤㅤㅤ
ㅤㅤㅤ
ㅤㅤㅤ
ㅤㅤㅤ
Walvax Publishes Immunogenicity and Safety Data
from Phase 3 Clinical Study of PCV13
in Frontiers in Microbiology
ㅤㅤㅤ
ㅤㅤㅤ
ㅤㅤㅤ
Walvax aims to become a high-quality, cost-effective and sustainable global vaccine producer.
We have abundant blockbuster pipelines in clinical stage, and keep investing a significant amount of revenue into R&D.
We have successfully developed and licensed 8 vaccines and protected hundreds of millions of people from diseases.
Founded in 2001, Walvax is mainly engaged in research and development, manufacturing and distribution of safe and efficacious vaccines. With the purpose of “Help everyone live a healthy life”, Walvax aims to be a leader in public health, sustainably providing high-quality and innovative products to protect against the world’s deadliest diseases.